Early tumor shrinkage and depth of response predict long-term outcome in metastatic colorectal cancer patients treated with first-line chemotherapy plus bevacizumab: results from phase III TRIBE trial by the Gruppo Oncologico del Nord Ovest-Reference-Cited by-同舟云学术

Early tumor shrinkage and depth of response predict long-term outcome in metastatic colorectal cancer patients treated with first-line chemotherapy plus bevacizumab: results from phase III TRIBE trial by the Gruppo Oncologico del Nord Ovest

Published:2015-06 Issue:6 Volume:26 Page:1188-1194
ISSN:0923-7534
Container-title:Annals of Oncology
language:en
Short-container-title:Annals of Oncology

Author:

Cremolini C.,Loupakis F.,Antoniotti C.,Lonardi S.,Masi G.,Salvatore L.,Cortesi E.,Tomasello G.,Spadi R.,Zaniboni A.,Tonini G.,Barone C.,Vitello S.,Longarini R.,Bonetti A.,D'Amico M.,Di Donato S.,Granetto C.,Boni L.,Falcone A.

Publisher

Elsevier BV

Subject

Oncology,Hematology

Link

http://academic.oup.com/annonc/article-pdf/26/6/1188/16699866/mdv112.pdf

Reference13 articles.

1. Neoadjuvant treatment of unresectable colorectal liver metastases: correlation between tumour response and resection rates;Folprecht;Ann Oncol,2005

2. Relation between tumour response to first-line chemotherapy and survival in advanced colorectal cancer: a meta-analysis. Meta-Analysis Group in Cancer;Buyse;Lancet,2000

3. New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada;Therasse;J Natl Cancer Inst,2000

4. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1);Eisenhauer;Eur J Cancer,2009

5. Use of early tumor shrinkage to predict long-term outcome in metastatic colorectal cancer treated with cetuximab;Piessevaux;J Clin Oncol,2013

Cited by 160 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Early tumor shrinkage as a prognostic predictor in chemotherapy-naïve patients with locally advanced pancreatic cancer treated with modified FOLFIRINOX or gemcitabine plus nab-paclitaxel combination therapy: An exploratory analysis of JCOG1407;Pancreatology;2024-09

2. Immune‐inflammatory markers and clinical characteristics as predictors of the depth of response and prognosis of patients with PD‐L1 ≥50% metastatic non‐small cell lung cancer receiving first‐line immunotherapy;Thoracic Cancer;2024-08-27

3. Evaluation of the prognosis in patients with small-cell lung cancer treated by chemotherapy using tumor shrinkage rate-based radiomics;European Journal of Medical Research;2024-08-02

4. The Interplay between the DNA Damage Response (DDR) Network and the Mitogen-Activated Protein Kinase (MAPK) Signaling Pathway in Multiple Myeloma;International Journal of Molecular Sciences;2024-06-26

5. Prognostic value of the tumor-to-liver density ratio in patients with metastatic colorectal cancer treated with bevacizumab-based chemotherapy. A post-hoc study of the STIC-AVASTIN trial;Cancer Imaging;2024-06-17